Antiviral drug resistance increases hepatocellular carcinoma: A prospective decompensated cirrhosis cohort study

Figure 1 Flow chart of enrolled patients. NUCs: Nucleos(t)ide analogues; HCC: Hepatocellular carcinoma; DR: Drug-resistant; CVR: Complete virologic response; LAM: Lamivudine; ADV: Adefovir; LDT: Telbivudine; ETV: Entecavir; HCV: Hepatitis C virus.

Figure 2 Child-Pugh score (A) and sequential change of serum hepatitis B virus DNA level (B) in the course of antiviral therapy over 2 years.

Figure 3 Kaplan-Meier curve. Kaplan-Meier curve for incidence of hepatocellular carcinoma (HCC) in drug resistance (DR), complete virologic response (CVR) and control group was shown (A). The two-year cumulative incidence of HCC was extremely higher in rescue therapy failure group (B). However, no significant difference was seen in two years cumulative survival between DR group and CVR group as well as between the subgroup of failed rescue therapy and successful rescue therapy (C and D).The cumulative incidence of liver failure was higher in the control group than in the DR, CVR (E). However, there was no significant difference between failed rescue therapy and successful rescue therapy subgroups (F).